Evaluation of oocyte morphology in poor responders receiving testosterone before stimulation

Authors

Keywords:

androgen, in vitro fertilization, oocytes, ovarian retrieval, testosterone

Abstract

Introduction: Poor ovarian response is a significant challenge in assisted reproduction, and androgens have been associated with improved ovarian response.

Objective: To evaluate the impact of transdermal testosterone gel used prior to ovarian stimulation on oocyte quantity and quality in poor responders.

Methods: In this prospective study, 110 patients with poor ovarian response were randomized into two groups. Group 1 received transdermal testosterone gel for 21 days before ovarian stimulation, while group 2 (control) did not. Oocyte number, morphology, and maturity were assessed.

Results: The number of follicles ≥17 mm in group 1 was significantly higher than in group 2 (4.5 ± 1.7 vs. 2.6 ± 2.1, p = 0.00). Spherical, smooth polar bodies were more frequent in group 1 than in group 2 (75.7% vs. 66.1%; p = 0.02). The rate of metaphase II oocytes was significantly higher in group 1 compared to group 2 (89.6% vs. 81.9%, p = 0.02), as was the fertilization rate (84.1% vs. 74%, p=0.02).

Conclusions: Pretreatment with transdermal testosterone gel may improve both the quantity and quality of oocytes in poor responders undergoing in vitro fertilization.

Downloads

Download data is not yet available.

References

1. Guardo FD, Blockeel C, Vos MD, Palumbo M, Christoforidis N, Tournaye H, et al. Poor ovarian response and the possible role of natural and modified natural cycles [Internet]. Therapeutic advances in reproductive health. 2022; 16:1-8. DOI: 10.1177/26334941211062026

2. Lebovitz O, Haas J, Mor N, Zilberberg E, Aizer A, Kirshenbaum M, et al. Predicting IVF outcome in poor ovarian responders [Internet]. BMC Womens Health. 2022; 22(1):395. DOI: 10.1186/s12905-022-01964-y

3. Galatis D, Kalopita K, Grypiotis I, Flessas I, Kiriakopoulos N, Micha G, et al. Researching the Phenomenon of Poor Ovarian Responders and Management Strategies in IVF: A Narrative Review [Internet]. Acta Med Acad. 2022; 51(2):108-22. DOI: 10.5644/ama2006-124.379

4. Meldrum DR, Chang RJ, Giudice LC, Balasch J, Barbieri RL. Role of decreased androgens in the ovarian response to stimulation in older women [Internet]. Fertility sterility. 2013; 99(1):5-11. DOI: 10.1016/j.fertnstert.2012.10.011

5. Polyzos NP, Martinez F, Blockeel C, Gosalvez A, Fuente L, Pinborg A, et al. O-066 transdermal testosterone prior to ovarian stimulation for in vitro fertilization in women with poor ovarian response [Internet]. A multicenter multinational double-blind placebo-controlled randomized trial (the t-transport) [Internet]. Human Reproduction. 2023; 38(Supplement_1):dead093.080. DOI: 10.1093/humrep/dead093.080

6. Subirá J, Algaba A, Vázquez S, Taroncher DR, Mollá RG, Monzó FS, et al. Testosterone does not improve ovarian response in Bologna poor responders: a randomized controlled trial (testoprim) [Internet]. Reproductive BioMedicine Online. 2021; 43(3):466-74. DOI: 10.1016/j.rbmo.2021.05.021

7. Sharma N, Nayar KD. The effect of transdermal testosterone gel pretreatment on IVF outcomes in patients with poor ovarian reserve [Internet]. Journal of South Asian Federation of Obstetrics Gynaecology. 2023; 15(4):419-23. DOI: 10.5005/jp-journals-10006-2278

8. Esparza MEE, Ruvalcaba JLL, Salazar CGS, Salazar JC. Use of transdermal testosterone in women Poseidon IV group under high complexity assisted reproduction treatment [Internet]. Journal of IVF-Worldwide. 2024; 2(1):12-9. DOI:10.46989/001c.92149

9. Hoang QH, Ho HS, Do HT, Nguyen TV, Nguyen HP, Le MT. Therapeutic effect of prolonged testosterone pretreatment in women with poor ovarian response: A randomized control trial [Internet]. Reproductive Medicine Biology. 2021; 20(3):305-12. DOI: 10.1002/rmb2.12383

10. Ebner T, Yaman C, Moser M, Sommergruber M, Feichtinger O, Tews G. Prognostic value of first polar body morphology on fertilization rate and embryo quality in intracytoplasmic sperm injection [Internet]. Human Reproduction. 2000; 15(2):427-30. DOI: 10.1093/humrep/15.2.427

11. Kahraman S, Yakin K, Dönmez E, Samli H, Bahçe M, Cengiz G, et al. Relationship between granular cytoplasm of oocytes and pregnancy outcome following intracytoplasmic sperm injection [Internet]. Human Reproduction. 2000; 15(11):2390-3. DOI: 10.1093/humrep/15.11.2390

12. Nikiforov D, Grøndahl ML, Hreinsson J, Andersen CY. Human oocyte morphology and outcomes of infertility treatment: a systematic review [Internet]. Reproductive Sciences. 2022; 29(10): 2768-85. DOI: 10.1007/s43032-021-00723-y

13. Sciorio R, Tramontano L, Greco PF, Greco E. Morphological assessment of oocyte quality during assisted reproductive technology cycle [Internet]. JBRA Assist Reprod. 2024; 28(3):511-20. DOI: 10.5935/1518-0557.20240034

14. Fischer NM, Nguyen HV, Singh B, Baker VL, Segars JH Prognostic value of oocyte quality in assisted reproductive technology outcomes: a systematic review [Internet]. Reviews. 2021; 2(2):120-39. DOI: 10.1016/j.xfnr.2021.03.001

15. Balaban B, Keles I, Ebner T. Morphological assessment of oocyte quality [Internet]. Manual of Oocyte Retrieval Preparation in Human Assisted Reproduction. 2022; 85-97. DOI: 10.1017/9781108891646

16. Singh N, Parimalam P, Kumar S, Vanamail P. Role of transdermal testosterone gel pre-treatment on IVF outcome: a prospective randomized controlled trial with active control [Internet]. International Journal of Reproduction, Contraception, Obstetrics Gynecology. 2021; 10(9):3509-15. DOI: 10.18203/2320-1770.ijrcog20213476

17. Solernou R, Peralta S, Casals G, Guimera M, Solsona M, Borras A, et al. The Follicular Output Rate (FORT) as a method to evaluate transdermal testosterone efficacy in poor responders [Internet]. JBRA Assist Reprod. 2021; 25(2):229-34. DOI: 10.5935/1518-0557.20200086

18. Nayar K, Kaur G, Sanan S, Aggarwal S, Kant G. O-068 Transdermal testosterone gel (TTG) pre-treatment duration in improving ivf outcome in patients with poor prognosis (poseidon group 3 and 4): A randomised controlled trial [Internet]. Human Reproduction. 2023; 38(Supplement_1):dead093.082. DOI: 10.1093/humrep/dead093.082

19. Nayar K, Gupta S, Bhattacharya R, Mehra P, Mishra J, Kant G. P–612 Transdermal testosterone vs. Placebo (lubricant gel) pre-treatment in improving IVF outcomes in diminished ovarian reserve patients (Poseidon group 3 and 4): a randomised controlled trial [Internet]. Human Reproduction. 2021; 36(Supplement_1):deab130. 611. DOI: 10.1093/humrep/deab130.611

20. Sipe CS, Thomas MR, Stegmann BJ, Van VBJ. Effects of exogenous testosterone supplementation in gonadotrophin stimulated cycles [Internet]. Human Reproduction. 2010; 25(3):690-696. DOI: 10.1093/humrep/dep442

Downloads

Published

2025-12-03

How to Cite

1.
Doan Thi H, Trinh TS, Nguyen TT, Nguyen MP, Trinh AT, Tran VT, et al. Evaluation of oocyte morphology in poor responders receiving testosterone before stimulation. Rev. cuba. med. mil [Internet]. 2025 Dec. 3 [cited 2025 Dec. 5];54(4):e025076760. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/76760

Issue

Vol. 54 No. 4 (2025): October - December (In Progress)

Section

Research Article

License

Copyright (c) 2025 Hang Doan Thi, The Son Trinh, Thanh Tung Nguyen, Minh Phuong Nguyen, An Thien Trinh, Van Tuan Tran, Ngoc Nhat Nguyen , Quoc Thanh Trinh

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Authors who have publications with this Journal accept the following terms:

  • The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
  • The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
  • Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.